Compare VENUS REMEDIES with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ABBOTT INDIA VENUS REMEDIES/
ABBOTT INDIA
 
P/E (TTM) x -14.6 52.5 - View Chart
P/BV x 1.0 17.0 5.7% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 VENUS REMEDIES   ABBOTT INDIA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ABBOTT INDIA
Mar-19
VENUS REMEDIES/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1268,834 1.4%   
Low Rs615,458 1.1%   
Sales per share (Unadj.) Rs301.81,731.1 17.4%  
Earnings per share (Unadj.) Rs-24.9211.9 -11.7%  
Cash flow per share (Unadj.) Rs2.5219.9 1.2%  
Dividends per share (Unadj.) Rs065.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs293.3945.2 31.0%  
Shares outstanding (eoy) m12.3421.25 58.1%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.34.1 7.5%   
Avg P/E ratio x-3.833.7 -11.1%  
P/CF ratio (eoy) x36.732.5 113.1%  
Price / Book Value ratio x0.37.6 4.2%  
Dividend payout %030.7 0.0%   
Avg Mkt Cap Rs m1,154151,848 0.8%   
No. of employees `0000.93.5 26.5%   
Total wages/salary Rs m3934,356 9.0%   
Avg. sales/employee Rs Th4,026.110,555.5 38.1%   
Avg. wages/employee Rs Th425.01,249.9 34.0%   
Avg. net profit/employee Rs Th-331.81,292.2 -25.7%   
INCOME DATA
Net Sales Rs m3,72436,786 10.1%  
Other income Rs m231,133 2.0%   
Total revenues Rs m3,74737,919 9.9%   
Gross profit Rs m3956,047 6.5%  
Depreciation Rs m338169 199.9%   
Interest Rs m35423 1,574.7%   
Profit before tax Rs m-2756,989 -3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m322,485 1.3%   
Profit after tax Rs m-3074,503 -6.8%  
Gross profit margin %10.616.4 64.5%  
Effective tax rate %-11.535.6 -32.3%   
Net profit margin %-8.212.2 -67.3%  
BALANCE SHEET DATA
Current assets Rs m2,63827,610 9.6%   
Current liabilities Rs m2,3058,569 26.9%   
Net working cap to sales %8.951.8 17.3%  
Current ratio x1.13.2 35.5%  
Inventory Days Days13560 224.9%  
Debtors Days Days4627 169.1%  
Net fixed assets Rs m4,8711,057 460.9%   
Share capital Rs m123213 58.1%   
"Free" reserves Rs m3,49619,873 17.6%   
Net worth Rs m3,61920,086 18.0%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50929,409 25.5%  
Interest coverage x0.2311.6 0.1%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.3 39.7%   
Return on assets %0.615.4 4.1%  
Return on equity %-8.522.4 -37.8%  
Return on capital %1.634.9 4.5%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m0369 0.0%   
Fx outflow Rs m5174,918 10.5%   
Net fx Rs m-517-4,549 11.4%   
CASH FLOW
From Operations Rs m5144,991 10.3%  
From Investments Rs m-123-2,570 4.8%  
From Financial Activity Rs m-387-1,428 27.1%  
Net Cashflow Rs m4993 0.4%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 7.9 2.3%  
FIIs % 0.6 0.1 580.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.1 388.3%  
Shareholders   20,121 18,270 110.1%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   UNICHEM LAB  SUN PHARMA  IPCA LABS  GLENMARK PHARMA  NEULAND LABS  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Zoomed 613 Points Today(Closing)

Indian share markets extended gains as the session progressed and ended on a strong note.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


May 18, 2021 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS